Cargando…
Polatuzumab Vedotin联合利妥昔单抗和苯达莫司汀治疗复发/难治性弥漫大B细胞淋巴瘤的单中心疗效和安全性分析
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Editorial office of Chinese Journal of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980657/ https://www.ncbi.nlm.nih.gov/pubmed/35231996 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.01.013 |
| _version_ | 1784681442440118272 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8980657 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Editorial office of Chinese Journal of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89806572022-04-06 Polatuzumab Vedotin联合利妥昔单抗和苯达莫司汀治疗复发/难治性弥漫大B细胞淋巴瘤的单中心疗效和安全性分析 Zhonghua Xue Ye Xue Za Zhi 短篇论著 Editorial office of Chinese Journal of Hematology 2022-01 /pmc/articles/PMC8980657/ /pubmed/35231996 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.01.013 Text en 2022年版权归中华医学会所有 https://creativecommons.org/licenses/by/3.0/This work is licensed under a Creative Commons Attribution 3.0 License. |
| spellingShingle | 短篇论著 Polatuzumab Vedotin联合利妥昔单抗和苯达莫司汀治疗复发/难治性弥漫大B细胞淋巴瘤的单中心疗效和安全性分析 |
| title | Polatuzumab Vedotin联合利妥昔单抗和苯达莫司汀治疗复发/难治性弥漫大B细胞淋巴瘤的单中心疗效和安全性分析 |
| title_full | Polatuzumab Vedotin联合利妥昔单抗和苯达莫司汀治疗复发/难治性弥漫大B细胞淋巴瘤的单中心疗效和安全性分析 |
| title_fullStr | Polatuzumab Vedotin联合利妥昔单抗和苯达莫司汀治疗复发/难治性弥漫大B细胞淋巴瘤的单中心疗效和安全性分析 |
| title_full_unstemmed | Polatuzumab Vedotin联合利妥昔单抗和苯达莫司汀治疗复发/难治性弥漫大B细胞淋巴瘤的单中心疗效和安全性分析 |
| title_short | Polatuzumab Vedotin联合利妥昔单抗和苯达莫司汀治疗复发/难治性弥漫大B细胞淋巴瘤的单中心疗效和安全性分析 |
| title_sort | polatuzumab vedotin联合利妥昔单抗和苯达莫司汀治疗复发/难治性弥漫大b细胞淋巴瘤的单中心疗效和安全性分析 |
| topic | 短篇论著 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980657/ https://www.ncbi.nlm.nih.gov/pubmed/35231996 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.01.013 |
| work_keys_str_mv | AT polatuzumabvedotinliánhélìtuǒxīdānkànghéběndámòsītīngzhìliáofùfānánzhìxìngmímàndàbxìbāolínbāliúdedānzhōngxīnliáoxiàohéānquánxìngfēnxī AT polatuzumabvedotinliánhélìtuǒxīdānkànghéběndámòsītīngzhìliáofùfānánzhìxìngmímàndàbxìbāolínbāliúdedānzhōngxīnliáoxiàohéānquánxìngfēnxī AT polatuzumabvedotinliánhélìtuǒxīdānkànghéběndámòsītīngzhìliáofùfānánzhìxìngmímàndàbxìbāolínbāliúdedānzhōngxīnliáoxiàohéānquánxìngfēnxī AT polatuzumabvedotinliánhélìtuǒxīdānkànghéběndámòsītīngzhìliáofùfānánzhìxìngmímàndàbxìbāolínbāliúdedānzhōngxīnliáoxiàohéānquánxìngfēnxī AT polatuzumabvedotinliánhélìtuǒxīdānkànghéběndámòsītīngzhìliáofùfānánzhìxìngmímàndàbxìbāolínbāliúdedānzhōngxīnliáoxiàohéānquánxìngfēnxī |